NR 566
Midterm Exam
One hundred multiple-choice questions covering
prescriptive authority, controlled substances, anti-
infective therapy, immunizations, and respiratory
pharmacology. Every item includes the correct answer and
a detailed rationale explaining the best response and key
distractors.
Advanced Pharmacology · Chamberlain College of Nursing
100 Questions | Detailed Answer Rationales | Weeks 1–4 Content
2026 E DITION
,NR 566 Midterm Exam (2026) Chamberlain Advanced Pharmacology
NR 566 Midterm Exam (2026)
Advanced Pharmacology | Chamberlain College of Nursing
100 multiple-choice questions with correct answers and detailed rationales. Content reflects weeks 1-4 of the course:
prescriptive authority, controlled substances, anti-infective therapy, immunizations, and respiratory pharmacology.
1. A newly certified family nurse practitioner asks which level of government
primarily defines and regulates her prescriptive authority. The NP should be taught
that prescriptive authority for APRNs is primarily governed by:
A. Federal law administered by the Drug Enforcement Administration
B. The American Nurses Association Scope and Standards of Practice
C. Individual state nurse practice acts and boards of nursing
D. The Joint Commission accreditation standards for medication management
Correct Answer: C
Rationale: Prescriptive authority is a legal grant that comes from state legislation, specifically the nurse practice act
and the state board of nursing, which define whether the NP practices under full, reduced, or restricted authority. The
DEA does register prescribers for controlled substances, but federal registration is meaningless without state-granted
authority. The ANA issues professional standards and the Joint Commission accredits organizations, but neither body
grants legal prescriptive authority.
2. An NP relocates to a state that grants full practice authority. Which prescribing
activity is this NP now legally permitted to perform without a physician
collaborative agreement?
A. Prescribing only noncontrolled legend drugs
B. Prescribing any Schedule II drug with a mandatory physician co-
signature on each prescription
C. Prescribing controlled and noncontrolled medications independently after
obtaining DEA registration
D. Prescribing only under a written protocol reviewed monthly by a collaborating
physician
Correct Answer: C
Rationale: Full practice authority permits the NP to evaluate patients, diagnose, and prescribe independently,
including controlled substances once the NP holds an individual DEA registration. Option A understates full
authority by excluding controlled substances. Requiring a co-signature or a physician-supervised protocol describes
reduced or restricted practice, not full practice authority.
Questions and Answers with Rationales 1
,NR 566 Midterm Exam (2026) Chamberlain Advanced Pharmacology
3. A drug has completed early human testing and now enters large, randomized,
controlled trials involving several thousand patients who have the target disease.
The primary purpose of this stage of clinical development is to:
A. Determine a safe dosage range and identify gross pharmacologic
effects in healthy volunteers
B. Evaluate effectiveness in a few hundred patients with the disease while
refining dose ranges
C. Confirm efficacy and continue safety monitoring in large patient
populations before approval
D. Perform postmarketing surveillance for rare adverse events after the
drug reaches the market
Correct Answer: C
Rationale: Phase III trials enroll large numbers of patients with the target disease to statistically confirm efficacy and
to further characterize safety immediately before FDA review. Healthy volunteer dosing and safety describes Phase
I, while a few hundred diseased patients describe Phase II. Postmarketing surveillance describes Phase IV, which
occurs only after approval.
4. During a pharmacology review, an NP correctly explains that the boxed
warning (black box warning) placed in a drug's labeling represents:
A. A prohibition on generic substitution for that product
B. A notice that the drug has been recalled from the market
C. The strongest FDA safety warning, calling attention to serious or life-
threatening risks
D. An advisory that the drug may be used only in hospitalized patients
Correct Answer: C
Rationale: A boxed warning is the most prominent safety warning the FDA can require in drug labeling, and it flags
serious or potentially life-threatening adverse effects so prescribers can weigh risks and counsel patients. It does not
ban generic substitution, indicate a recall, or restrict use to inpatient settings. Many commonly prescribed drugs,
including fluoroquinolones and montelukast, carry boxed warnings yet remain in wide use with appropriate patient
selection.
Questions and Answers with Rationales 2
, NR 566 Midterm Exam (2026) Chamberlain Advanced Pharmacology
5. A pediatric NP prescribes ondansetron for chemotherapy-induced nausea in a
manner not described in the FDA-approved labeling but supported by strong
published evidence. This action is:
A. Illegal, because off-label prescribing violates federal drug law
B. Legal and acceptable when supported by evidence and in the patient's best
interest
C. Permitted only for physicians and dentists, not for APRNs
D. Allowed only after the NP obtains case-by-case approval from the FDA
Correct Answer: B
Rationale: Off-label prescribing is legal, common, and often necessary in pediatrics, oncology, and pregnancy; the
clinician's duty is to ensure sound evidence and documented benefit to the patient. No federal law restricts off-label
use to physicians, and the FDA regulates drug approval and marketing rather than individual prescribing decisions.
Requiring FDA approval for each patient would make many accepted practices impossible.
6. A pharmacy offers to substitute a generic product for a brand-name antiepileptic.
For the generic to be considered therapeutically equivalent, it must:
A. Contain the same inactive fillers, dyes, and manufacturing processes as the
brand
B. Be priced at least 80 percent below the brand-name product
C. Deliver the same active ingredient at the same rate and extent of absorption,
demonstrating bioequivalence
D. Match the brand product in tablet color, shape, and scoring
Correct Answer: C
Rationale: Generic equivalence rests on containing the identical active ingredient in the same strength and
demonstrating bioequivalence, meaning comparable rate and extent of absorption. Inactive ingredients and
appearance may differ, and price is irrelevant to therapeutic equivalence. Matching color or shape has no
pharmacologic significance, although it may affect patient acceptance.
7. An 82-year-old woman requests something for chronic insomnia and asks about an
over-the-counter option. Using the AGS Beers Criteria, which medication should the
NP avoid prescribing to older adults?
A. Diphenhydramine
B. Melatonin
C. Low-dose trazodone
D. Ramelteon
Questions and Answers with Rationales 3